<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col align="left" valign="top" width="50%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Interacting Drug</th>
<th align="center" stylecode="Rrule">Interaction</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Drugs known to prolong QT interval (e.g., Class IA and Class III antiarrhythmic agents).</td>
<td stylecode="Rrule">QUALAQUIN prolongs QT interval, ECG abnormalities including QT prolongation and Torsades de Pointes. Avoid concomitant use (<linkhtml href="#S5.3">5.3</linkhtml>).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Other antimalarials (e.g., halofantrine, mefloquine).</td>
<td stylecode="Rrule">ECG abnormalities including QT prolongation. Avoid concomitant use (<linkhtml href="#S5.3">5.3</linkhtml>,<linkhtml href="#S7.2"> 7.2</linkhtml>).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">CYP3A4 inducers or inhibitors</td>
<td stylecode="Rrule">Alteration in plasma quinine concentration. Monitor for lack of efficacy or increased adverse events of quinine (<linkhtml href="#S7.1">7.1</linkhtml>).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">CYP3A4 and CYP2D6 substrates</td>
<td stylecode="Rrule">Quinine is an inhibitor of CYP3A4 and CYP2D6. Monitor for lack of efficacy or increased adverse events of the co-administered drug (<linkhtml href="#S7.2">7.2</linkhtml>).</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Digoxin</td>
<td stylecode="Rrule">Increased digoxin plasma concentration (<linkhtml href="#S5.8">5.8</linkhtml>,<linkhtml href="#S7.1"> 7.1</linkhtml>).</td>
</tr>
</tbody>
</table>